Clinical Trials
11 trialsNCT06734533 2024-12-16
Anlotinib-based Combination Therapy in Patients with Hormone Receptor-positive（HR+） Metastatic Breast Cancer(MBC) .
Hunan Cancer Hospital
Recruiting
NCT06525675 2024-12-13
Study to Evaluate the Extended Overall Survival (OS) Data From PARSIFAL Study (The PARSIFAL-LONG Study)
MedSIR
Completed
NCT06341283 2024-05-10
A Retrospective Real-world Study of Abemaciclib in HR+ Breast Cancer
The Affiliated Hospital of Qingdao University
Not yet recruiting
NCT05427617 2022-06-22
ACTDNAGLT
Hunan Cancer Hospital
Completed
NCT02909361 2022-04-20
Fulvestrant 500mg in Patients With Advanced Breast Cancer
Fudan University
Unknown
NCT04852081 2021-04-21
Analysis of Therapy Sequence in Women With HR+, HER2 - mBC in Moscow: A Multicenter Retrospective Observational Study.
Blokhin's Russian Cancer Research Center
Unknown
NCT04524728 2020-08-24
Patterns of Treatment and Outcome of Palbociclib Plus Endocrine Therapy
Istituti Clinici Scientifici Maugeri SpA
Completed
NCT04258163 2020-02-10
Association of Survival With Maintenance Therapy in Patients With Metastatic Breast Cancer After First-line Chemotherapy
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Completed
NCT03925233 2019-04-24
Breast Cancer Treatment Based on Organ-like Culture
Xijing Hospital
Unknown
NCT01509625 2016-06-01
EFFICACY
Hospital Clinico Universitario San Cecilio
Completed
NCT01399086 2012-03-13
Fulvestrant in Postmenopausal Patients With Metastatic Breast Cancer
Hellenic Oncology Research Group
Completed